RedHill Biopharma Ltd (RDHL)

[Crusader]

Well that was good for a modest 5% pop up,

but it’s fading some as the stock market discounts the obvious: the lung complications addressed by RDHL’s proposed treatment are really complications in common with all Covid strains.

Now when RDHL announces the CT results in a few weeks, 5% will be a small factorial of the move up which will be sustained as we approach FDA Emergency approval.

Right?